Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor-Reference-Cited by-同舟云学术

Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor

Published:2004-01 Issue:1 Volume:14 Page:251-256
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Yip Yvonne,Victor Frantz,Lamar Jason,Johnson Robert,Wang Q.May,Barket Donna,Glass John,Jin Ling,Liu Lifei,Venable Daryl,Wakulchik Mark,Xie Congping,Heinz Beverly,Villarreal Elcira,Colacino Joe,Yumibe Nathan,Tebbe Mark,Munroe John,Chen Shu-Hui

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference30 articles.

1. Emerging therapies for hepatitis C virus infection

2. Novel Approaches to the Treatment of Hepatitis C Virus Infection

3. Molecular virology of hepatitis C virus.

4. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

5. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir;Nature Microbiology;2024-03-29

2. Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead;Journal of Medicinal Chemistry;2024-02-09

3. Discovery of novel anti-infective agents;Advances in Pharmacology;2024

4. Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Covalent Warhead;2023-10-25

5. Discovery of novel bicyclic[3.3.0]proline peptidyl α-ketoamides as potent 3CL-protease inhibitors for SARS-CoV-2;Bioorganic & Medicinal Chemistry Letters;2023-06